Vijaya Diagnostic Centre has released its financial results for the quarter and year ended March 31, 2026. The Board of Directors recommended a final dividend of ₹2 per share, representing a 200% payout. Additionally, the company announced the strategic acquisition of the MRI, EEG, and NCV services business from its wholly-owned subsidiary for ₹4.20 crore and revealed new employee stock option grants as part of its growth and talent retention strategy.
Financial Performance and Dividend
Following the meeting held on May 7, 2026, the company announced its audited standalone and consolidated financial results for the period ending March 31, 2026. Shareholders are set to benefit from a final dividend of ₹2 per equity share, subject to approval at the upcoming Annual General Meeting. This dividend reflects the company’s commitment to returning value to its investors, representing a 200% return on the ₹1 face value of each share.
Strategic Business Expansion
The company has approved the acquisition of the MRI, EEG, and NCV services business from its subsidiary, Medinova Millennium MRI Services LLP. The deal is valued at approximately ₹4.20 crore. This acquisition is expected to streamline operations and align the services more closely with the company’s core strategic objectives. The transaction is projected to be completed within 3 months.
Leadership and Talent Initiatives
The Board noted that Dr. D. Nageshwar Reddy will not be seeking re-appointment for a second term as an Independent Director upon the completion of his current term on May 25, 2026, due to his other professional commitments. To drive future performance and retention, the company has also granted 1,79,500 Employee Stock Options (ESOPs). These options are exercisable over a period of 10 years and are tied to specific vesting schedules and performance metrics for eligible employees in support and senior management functions.
Operational Updates
In addition to these strategic moves, the company confirmed the re-appointment of M/s. Santhosh & Associates as Cost Auditors for the 2026-27 financial year. These collective decisions reflect the company’s focus on maintaining strong corporate governance while aggressively pursuing its expansion and talent development goals in the diagnostics sector.
Source: BSE
